专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070190027A1 Targeting of Herpes simplex virus to specific receptors 有权
标题翻译：单纯疱疹病毒靶向特异性受体
公开(公告)号：US20070190027A1
公开(公告)日：2007-08-16
申请号：US11215636
申请日：2005-08-30
申请人： Guoying Zhou , Bernard Roizman
发明人： Guoying Zhou , Bernard Roizman
IPC分类号： A61K48/00 , C12N15/86 , C12Q1/70
CPC分类号： C12N15/86 , A61K47/642 , A61K47/6901 , A61K48/00 , C07K2319/74 , C12N2710/16643 , C12N2710/16645 , C12N2810/852
摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
摘要翻译：本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。此外，提供了用于生产这种HSV颗粒的重组载体。通过降低HSV对其天然受体的亲合力并增加对所选受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。选择性靶向细胞的能力使得HSV颗粒特别可用于选择性地诊断，治疗和成像携带所选择的结合对成员（例如受体）的细胞。本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。

2. 发明申请

US20160270837A1 ATRIAL SEPTAL ANEURYSM TRANSSEPTAL ACCESS SYSTEM 审中-公开
标题翻译： ATRIAL SEPTAL ANEURYSM TRANSSEPTAL访问系统
公开(公告)号：US20160270837A1
公开(公告)日：2016-09-22
申请号：US15035997
申请日：2014-11-17
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： ALAN CHENG , GEORGE COLES
IPC分类号： A61B18/02 , A61B17/34
CPC分类号： C12N7/00 , A61B17/3478 , A61B18/02 , A61B18/0218 , A61B2018/0038 , A61B2018/0212 , A61B2018/0275 , A61B2217/005 , C07K1/047 , C07K2319/03 , C07K2319/735 , C12N2710/16621 , C12N2710/16645 , C12N2810/855 , G01N33/566 , G01N33/6854 , G01N33/74 , G01N2333/70514 , G01N2333/726
摘要： A transseptal access stability system (TASS) and method of use thereof is disclosed. The TASS includes a venous sheath for reducing the likelihood of complications that may arise when performing transseptal punctures. The TASS uses either suction force or cryo-based energy for securing the fossa ovale against the rim of the orifice of the venous sheath. A method of performing a transseptal puncture using the presently disclosed TASS also is disclosed.
摘要翻译：公开了一种经验通道访问稳定系统（TASS）及其使用方法。 TASS包括静脉鞘，用于减少在进行经脉搏穿刺时可能出现并发症的可能性。 TASS使用抽吸力或基于低温的能量来将窝窝抵靠静脉鞘的孔的边缘固定。公开了使用当前公开的TASS进行经中心穿刺的方法。

3. 发明申请

US20090136452A1 TARGETING OF HERPES SIMPLEX VIRUS TO SPECIFIC RECEPTORS 有权
标题翻译：将特定病毒的简单病毒定向到特定受体
公开(公告)号：US20090136452A1
公开(公告)日：2009-05-28
申请号：US12065455
申请日：2006-08-30
申请人： Guoying Zhou , Bernard Roizman
发明人： Guoying Zhou , Bernard Roizman
IPC分类号： A61K35/76 , C12N7/00 , C12Q1/70 , C12N15/87
CPC分类号： C07K16/18 , A61K35/00 , A61K38/2086 , A61K47/642 , A61K47/6801 , A61K47/69 , A61K47/6901 , C07K14/5437 , C12N15/86 , C12N15/8695 , C12N2710/16632 , C12N2710/16643 , C12N2710/16645 , C12N2799/028 , C12N2810/50 , C12N2810/852 , C12Q1/705
摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
摘要翻译：本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。此外，提供了用于生产这种HSV颗粒的重组载体。通过降低HSV对其天然受体的亲合力并增加对所选受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。选择性靶向细胞的能力使HSV颗粒。特别可用于选择性地诊断，治疗和成像携带所选择的结合对成员例如受体的细胞。本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。

4. 发明申请

US20160250267A1 ONCOLYTIC HSV VECTOR 审中-公开
标题翻译： ONCOLYTIC HSV矢量
公开(公告)号：US20160250267A1
公开(公告)日：2016-09-01
申请号：US15032958
申请日：2014-10-28
申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： Hiroaki UCHIDA , Justus B. COHEN , Joseph C. GLORIOSO, III , Paola GRANDI
IPC分类号： A61K35/763 , C12N7/00
CPC分类号： A61K35/763 , C07K14/005 , C07K2319/33 , C12N7/00 , C12N2710/16621 , C12N2710/16622 , C12N2710/16632 , C12N2710/16641 , C12N2710/16643 , C12N2710/16645 , C12N2710/16662 , C12N2710/16671
摘要： The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
摘要翻译：本发明提供了一种重组溶瘤性单纯疱疹病毒（oHSV），其包含对细胞（例如癌细胞）表面上存在的分子（蛋白质，脂质或碳水化合物决定簇）特异的非HSV配体和一种或多种插入到一个或多个HSV基因座中的一个或多个microRNA靶序列的拷贝，优选在正常（即非癌性）细胞中HSV复制所需的一种或多种HSV基因。本发明还提供了包含本发明的oHSV的库存和药物组合物以及使用本发明的oHSV杀死肿瘤细胞的方法。

5. 发明申请

US20160175370A1 Targeting of Herpes Simplex Virus to Specific Receptors 审中-公开
标题翻译：将单纯疱疹病毒靶向特异性受体
公开(公告)号：US20160175370A1
公开(公告)日：2016-06-23
申请号：US14589581
申请日：2015-01-05
申请人： THE UNIVERSITY OF CHICAGO
发明人： Guoying Zhou , Bernard Roizman
IPC分类号： A61K35/763 , C07K16/18 , C07K14/54 , C12N7/00 , A61K47/48
CPC分类号： C07K16/18 , A61K35/00 , A61K38/2086 , A61K47/642 , A61K47/6801 , A61K47/69 , A61K47/6901 , C07K14/5437 , C12N15/86 , C12N15/8695 , C12N2710/16632 , C12N2710/16643 , C12N2710/16645 , C12N2799/028 , C12N2810/50 , C12N2810/852 , C12Q1/705
摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
摘要翻译：本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。此外，提供了用于生产这种HSV颗粒的重组载体。通过降低HSV对其天然受体的亲合力并增加对所选受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。选择性靶向细胞的能力使HSV颗粒特别适用于选择性诊断，治疗和成像携带所选结合对成员（如受体）的细胞。本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。

6. 发明授权

US09803006B2 Targeting of herpes simplex virus to specific receptors 有权
公开(公告)号：US09803006B2
公开(公告)日：2017-10-31
申请号：US14589581
申请日：2015-01-05
申请人： THE UNIVERSITY OF CHICAGO
发明人： Guoying Zhou , Bernard Roizman
IPC分类号： C07K14/00 , C07K16/18 , A61K47/48 , C07K14/54 , A61K38/20 , C12N15/869 , C12N15/86 , C12Q1/70 , A61K35/00
CPC分类号： C07K16/18 , A61K35/00 , A61K38/2086 , A61K47/642 , A61K47/6801 , A61K47/69 , A61K47/6901 , C07K14/5437 , C12N15/86 , C12N15/8695 , C12N2710/16632 , C12N2710/16643 , C12N2710/16645 , C12N2799/028 , C12N2810/50 , C12N2810/852 , C12Q1/705
摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

7. 发明申请

US20170035819A1 ONCOLYTIC HSV VECTOR 审中-公开
标题翻译： ONCOLYTIC HSV矢量
公开(公告)号：US20170035819A1
公开(公告)日：2017-02-09
申请号：US15204350
申请日：2016-07-07
申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education
发明人： Hiroaki Uchida , Justus B. Cohen , Joseph C. Glorioso, III , Paola Grandi
IPC分类号： A61K35/763 , C12N7/00
CPC分类号： A61K35/763 , C07K14/005 , C07K2319/33 , C12N7/00 , C12N2710/16621 , C12N2710/16622 , C12N2710/16632 , C12N2710/16641 , C12N2710/16643 , C12N2710/16645 , C12N2710/16662 , C12N2710/16671
摘要： The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
摘要翻译：本发明提供了一种重组溶瘤性单纯疱疹病毒（oHSV），其包含对细胞（例如癌细胞）表面上存在的分子（蛋白质，脂质或碳水化合物决定簇）特异的非HSV配体和一种或多种插入到一个或多个HSV基因座中的一个或多个microRNA靶序列的拷贝，优选在正常（即非癌性）细胞中HSV复制所需的一种或多种HSV基因。本发明还提供了包含本发明的oHSV的库存和药物组合物以及使用本发明的oHSV杀死肿瘤细胞的方法。

8. 发明申请

US20160355789A1 VIRION DISPLAY ARRAY FOR PROFILING FUNCTIONS AND INTERACTIONS OF HUMAN MEMBRANE PROTEINS 审中-公开
标题翻译： VIRION显示阵列用于人体膜蛋白的功能和相互作用
公开(公告)号：US20160355789A1
公开(公告)日：2016-12-08
申请号：US14900314
申请日：2014-06-20
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： HENG ZHU , PRASHANT DESAI , MIN LI , SHAOHUI HU
IPC分类号： C12N7/00 , G01N33/74 , G01N33/566 , G01N33/68
CPC分类号： C12N7/00 , A61B17/3478 , A61B18/02 , A61B18/0218 , A61B2018/0038 , A61B2018/0212 , A61B2018/0275 , A61B2217/005 , C07K1/047 , C07K2319/03 , C07K2319/735 , C12N2710/16621 , C12N2710/16645 , C12N2810/855 , G01N33/566 , G01N33/6854 , G01N33/74 , G01N2333/70514 , G01N2333/726
摘要： Provided herein are recombinant virion arrays comprising human membrane bound proteins that retain their native conformations and/or interactions, recombinant HSV-1 virions, and methods of use including high-content, high-throughput assays for screening for ligands and/or drugs that bind human membrane bound proteins, diagnostic assays, proteomic assays, and bio-sensor assays. Also provided are recombinant HSV-1 virions comprising an envelope comprising a plurality of heterologous membrane bound proteins that retain their native conformations and/or interactions as well as recombinant HSV-1 bacterial artificial chromosome (BAC) clones encoding heterologous membrane polypeptides.
摘要翻译：本文提供了包含保留其天然构象和/或相互作用的人膜结合蛋白的重组病毒粒子阵列，重组HSV-1病毒粒子，以及包括高含量，高通量测定法的筛选用于结合的配体和/或药物的高含量，高通量测定人膜结合蛋白，诊断测定，蛋白质组学测定和生物传感器测定。还提供了包含保持其天然构象和/或相互作用的多个异源膜结合蛋白以及编码异源膜多肽的重组HSV-1细菌人造染色体（BAC）克隆的包膜的重组HSV-1病毒粒子。

9. 发明申请

US20150374767A1 Treatment of Cancer 审中-公开
标题翻译：癌症治疗
公开(公告)号：US20150374767A1
公开(公告)日：2015-12-31
申请号：US14768549
申请日：2014-02-21
申请人： VIRTTU BIOLOGICS LIMITED
发明人： Joe CONNER
IPC分类号： A61K35/763 , G01N33/50 , A61K45/06
CPC分类号： A61K35/763 , A61K39/00 , A61K45/06 , A61K2039/525 , C07K14/005 , C07K14/52 , C07K14/5434 , C07K14/70578 , C12N2710/16641 , C12N2710/16643 , C12N2710/16645 , C12N2710/16662 , C12N2710/16671 , G01N33/5011 , G01N2500/04 , G01N2500/10 , A61K2300/00
摘要： A method of treating cancer is disclosed, the method comprising simultaneous or sequential administration of a virus and a receptor tyrosine kinase (RTK) inhibitor.
摘要翻译：公开了一种治疗癌症的方法，所述方法包括同时或顺序施用病毒和受体酪氨酸激酶（RTK）抑制剂。

10. 发明申请

US20170274025A1 ONCOLYTIC HSV VECTOR 审中-公开
公开(公告)号：US20170274025A1
公开(公告)日：2017-09-28
申请号：US15616585
申请日：2017-06-07
申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education
发明人： Hiroaki Uchida , Justus B. Cohen , Joseph C. Glorioso, III , Paola Grandi
IPC分类号： A61K35/763 , C07K14/005 , C12N7/00
CPC分类号： A61K35/763 , C07K14/005 , C07K2319/33 , C12N7/00 , C12N2710/16621 , C12N2710/16622 , C12N2710/16632 , C12N2710/16641 , C12N2710/16643 , C12N2710/16645 , C12N2710/16662 , C12N2710/16671
摘要： The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式